Figure 8. Schematic regulatory pathway of linagliptin in
OSI-906-induced hepatic steatosis.
Linagliptin improved hepatic steatosis induced by acute IR/IGF1R
signaling inhibition with OSI-906 through an insulin
signaling-independent pathway. Pathways involving perilipin-2, NNMT, and
sirtuins have been proposed as possible mechanisms for the amelioration
of OSI-906-induced hepatic steatosis by linagliptin.